Faron Pharmaceuticals OY (FARN) NPV
- Add to watchlist
- Create an alert
- This stock can be held in a
185.00p
193.00p
355.00p
£188.32 million
180.00p
180.00p
89.00p
n/a
10.00p (5.26%) Previous:
10.00p
20,435
n/a
750
Performance
1 week 1W | 5.88% | 1 year 1Y | 30.77% |
---|---|---|---|
1 month 1M | 14.29% | 2 years 2Y | 44.19% |
3 months 3M | 19.64% | 3 years 3Y | 41.94% |
6 months 6M | 87.5% | 5 years 5Y | 39.6% |
Performance figures are based on the previous close price. Past performance is not an indication of future performance.
Fundamental data
Year ending: | 31/12/2023 | 31/12/2022 |
---|---|---|
Revenue (€m) | n/a | n/a |
Profit before tax (€m) | (30.94) | (28.73) |
Adjusted EPS (¢): | (48.00) | (52.00) |
P/E ratio | n/a | n/a |
PEG | n/a | n/a |
EPS growth (%) | n/a | n/a |
Values are quoted in the stock's local currency: Euro
All fundamental dataDividend information for this stock is not available.
Dividend information for this stock is not available.
Ready to invest?
Important Documents
There are no documents available for this stock.
-
Faron Pharmaceuticals reports regulatory progress in the UK
2 December 2024 11:50
-
Faron announces promising MDS trial results
27 November 2024 11:39
-
Faron Pharmaceuticals files new patent for Clever-1
11 November 2024 13:52
-
Interactions with UK Regulatory Authorities
2 December 2024 08:00
-
Positive Phase 2 Interim Results from BEXMAB Trial
27 November 2024 07:00
-
Shareholders’ Nomination Board
5 November 2024 07:00
The London Stock Exchange does not disclose whether a trade is a buy or a sell so this data is estimated based on the trade price received and the LSE-quoted mid-price at the point the trade is placed. It should only be considered an indication and not a recommendation.
Trades priced above the mid-price at the time the trade is placed are labelled as a buy; those priced below the mid-price are sells; and those priced close to the mid-price or declared late are labelled 'N/A'.